Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 534 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TDF Clear all
Completed Phase 4 Interventional Results available

Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use

NCT03842436
View directory record Official record
Conditions
HIV/AIDS, Substance Use Disorders, Adherence, Medication
Interventions
Digital pill, Truvada
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boylston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 4 Interventional Results available

Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

NCT06104306
View directory record Official record
Conditions
HIV-1-infection
Interventions
B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Bakersfield, California • Palm Springs, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT01497899
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, E/C/F/TAF Placebo, E/C/F/TAF, E/C/F/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Not applicable Interventional

Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection

NCT00490412
View directory record Official record
Conditions
HIV Infections
Interventions
Vitamin D supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 4 Interventional Results available

Parrying the Pitfalls of PrEP: Project PEACH

NCT05072093
View directory record Official record
Conditions
HIV, STI
Interventions
PrEP discontinuation intervention, Offering of on-demand oral PrEP, Offering of STI PEP, Injectable PrEP
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 1 Interventional

Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression

NCT00336778
View directory record Official record
Conditions
HIV Infections
Interventions
3TC, TDF, NLV
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women

NCT03060785
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir Disoproxil Fumarate/Emtricitabine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 21, 2026, 3:37 PM EDT
Terminated Phase 3 Interventional Results available

Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors

NCT03887702
View directory record Official record
Conditions
Hepatitis B Infection, Malignant Solid Neoplasm
Interventions
Best Practice, Entecavir, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate
Other · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
192
States / cities
Fort Smith, Arkansas • Anaheim, California • Antioch, California + 140 more
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

NCT04143594
View directory record Official record
Conditions
HIV-1-infection
Interventions
Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
49
States / cities
Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 4 Interventional Results available

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

NCT01277601
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TDF, Peg-IFN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 21, 2026, 3:37 PM EDT
Terminated Phase 2 Interventional Results available

Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B

NCT00524173
View directory record Official record
Conditions
Hepatitis B
Interventions
Tenofovir & Emtricitabine, Tenofovir
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 4 Interventional

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

NCT00224445
View directory record Official record
Conditions
HIV Infections
Interventions
Truvada, Atazanavir, Ritonavir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 21, 2026, 3:37 PM EDT
Completed No phase listed Observational

Platelet Function on Abacavir and Tenofovir

NCT03081572
View directory record Official record
Conditions
Cardiovascular Diseases, Platelet Aggregation, Spontaneous, HIV/AIDS
Interventions
Platelet aggregation
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 21, 2026, 3:37 PM EDT
Not yet recruiting Phase 1 Interventional

Repurposing a Combination Antiretroviral Drug Therapy to Target Retrotransposons and Treat Early Alzheimer's Disease

NCT07795307
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Emtricitabine and tenofovir disoproxil fumarate combination, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B

NCT00117676
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TDF, ADV, TDF placebo, ADV placebo, FTC/TDF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
17
States / cities
La Jolla, California • Pasadena, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"

NCT05528653
View directory record Official record
Conditions
HIV Prevention
Interventions
Descovy
Drug
Lead sponsor
Vivent Health
Other
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Denver, Colorado • St Louis, Missouri • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 21, 2026, 3:37 PM EDT
Terminated No phase listed Observational

Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors

NCT01474954
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tenofovir Gel in Pregnancy and Lactation

NCT01136759
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir 1% gel, Placebo gel
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 21, 2026, 3:37 PM EDT
Not listed Phase 4 Interventional

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

NCT05463783
View directory record Official record
Conditions
HIV Infections, Obesity
Interventions
Biktarvy, Symtuza
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

NCT01338883
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Not applicable Interventional

Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression

NCT00344981
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
Tenofovir, Hydroxyurea
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

NCT02707601
View directory record Official record
Conditions
HIV-1 Infection, HCV Infection
Interventions
E/C/F/TAF, F/R/TAF, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

NCT01943799
View directory record Official record
Conditions
Chronic HBV Infection
Interventions
GS-4774, OAV Regimen
Biological · Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
16
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 21, 2026, 3:37 PM EDT
Completed Phase 4 Interventional Results available

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

NCT01270802
View directory record Official record
Conditions
HIV
Interventions
Tenofovir/emtricitabine, Tenofovir/emtricitabine/efavirenz, Raltegravir
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 21, 2026, 3:37 PM EDT